Sign in Subscribe

Alex Chompff

Phase 2 trial tests dostarlimab plus chemotherapy before surgery in stage III colon cancer

Skip to content The CRC Digest ◆ TRIAL DATA Phase 2 trial tests dostarlimab plus chemotherapy before surgery in stage III colon cancer The AZUR-4 trial is comparing neoadjuvant dostarlimab plus CAPEOX versus CAPEOX alone in previously untreated T4N0 or stage III mismatch repair proficient/microsatellite stable resectable colon cancer. (Clinical

Blood test shows promise for detecting advanced adenomas and colorectal cancer

Skip to content The CRC Digest ▪ SCREENING Blood test shows promise for detecting advanced adenomas and colorectal cancer The DENEB study developed and evaluated a novel blood-based assay designed to detect both advanced adenomas and colorectal cancer, addressing a key limitation of current blood tests by targeting premalignant lesions essential

CRC Research Update — August 10, 2026

Today's colorectal cancer research highlights

Metastatic Colon Cancer Reported in 15-Year-Old Patient

Skip to content The CRC Digest Metastatic Colon Cancer Reported in 15-Year-Old Patient A case report describes a 15-year-old with metastatic colon adenocarcinoma presenting with abdominal pain, highlighting that colorectal cancer is extremely rare in children and often associated with genetic predisposition syndromes such as Lynch syndrome or familial adenomatous

GPR39 Protein Linked to Immunotherapy Resistance in Microsatellite-Stable CRC

Skip to content The CRC Digest ◇ RESEARCH GPR39 Protein Linked to Immunotherapy Resistance in Microsatellite-Stable CRC Research using GPR39 knockdown in human and mouse CRC cell lines found that GPR39, a protein overexpressed in colorectal cancer, suppresses ferroptosis (a form of cell death) and reduces the sensitivity of microsatellite-stable tumors

Cancer Survivors Face Elevated Risk of Developing Colorectal Cancer

Skip to content The CRC Digest ♥ LIVING WITH CRC Cancer Survivors Face Elevated Risk of Developing Colorectal Cancer A Canadian cohort study of 172,928 non-colorectal cancer survivors found they have an elevated risk of developing subsequent primary colorectal cancers compared to the cancer-free population, suggesting tailored screening approaches may

Liquid Biopsies Can Monitor CRC Progression and Detect Residual Disease

Skip to content The CRC Digest ▪ RESEARCH Liquid Biopsies Can Monitor CRC Progression and Detect Residual Disease A translational science review in JAMA reports that circulating tumor DNA (ctDNA) sequencing can identify gene variants to inform treatment selection in colorectal cancer, and that detecting ctDNA after curative intent therapy correlates

Intensified Total Neoadjuvant Therapy Improves Survival in High-Risk Rectal Cancer

Skip to content The CRC Digest ◆ TRIAL DATA Intensified Total Neoadjuvant Therapy Improves Survival in High-Risk Rectal Cancer A Chinese phase III trial of 458 patients with high-risk locally advanced rectal cancer found that integrating long-course radiotherapy with uninterrupted capecitabine and oxaliplatin chemotherapy (doublet-LC TNT) achieved 3-year disease-free survival of

CRC Research Update — August 09, 2026

Today's colorectal cancer research highlights

ctDNA-Guided Treatment Decisions Show Mixed Results in Stage II and III Colon Cancer

Skip to content The CRC Digest ctDNA-Guided Treatment Decisions Show Mixed Results in Stage II and III Colon Cancer DYNAMIC-III found that escalation in ctDNA-positive stage III patients did not improve outcomes. (EClinicalMedicine) This content is informational only and does not constitute medical advice. Always consult your oncologist or care